Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL
Conditions: Primary Mediastinal Lymphoma Interventions: Drug: Cyclophosphamide; Drug: Doxorubicin Hydrochloride; Drug: Etoposide Phosphate; Drug: Prednisolone; Drug: Rituximab; Drug: Vincristine Sulfate; Drug: Filgrastim; Drug: Pegfilgrastim; Drug: Nivolumab 40 mg in 4 ml Injection Sponsors: National Research Center for Hematology, Russia Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 3, 2024 Category: Research Source Type: clinical trials
Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome
Conditions: Richter Syndrome Interventions: Drug: Glofitamab + Obinutuzumab Sponsors: French Innovative Leukemia Organisation; Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 1, 2024 Category: Research Source Type: clinical trials
Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout
Conditions: Tophaceous Gout; Prior Discontinued Use of Pegloticase Due to Failure Interventions: Drug: Rituximab Sponsors: University of California, Los Angeles Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 29, 2023 Category: Research Source Type: clinical trials
Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
Conditions: Diffuse Large B Cell Lymphoma Interventions: Drug: Polatuzumab Vedotin, Rituximab, Lenalidomide Sponsors: Yan Zhang, MD; Peking University Third Hospital; Peking University First Hospital; Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 20, 2023 Category: Research Source Type: clinical trials
Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera ® in Patients With Rheumatoid Arthritis
Conditions: Rheumatoid Arthritis Interventions: Drug: Rituximab; Drug: MabThera ® Sponsors: Mabscale, LLC Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 18, 2023 Category: Research Source Type: clinical trials
Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma Interventions: Drug: BEBT-908 for Injection; Drug: Rituximab Injection; Drug: Gemcitabine Hydrochloride for Injection; Drug: Oxaliplatin Injection; Drug: Etoposide Injection; Drug: Ifosfamide for Injection; Drug: Carboplatin Injection Sponsors: BeBetter Med Inc Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 11, 2023 Category: Research Source Type: clinical trials
A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Conditions: Relapsed/Refractory Follicular Lymphoma; Marginal Zone Lymphoma (MZL) Interventions: Drug: Odronextamab; Drug: Lenalidomide; Drug: Rituximab Sponsors: Regeneron Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 28, 2023 Category: Research Source Type: clinical trials
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
Conditions: Lymphoma, Mantle-Cell Interventions: Drug: Zanubrutinib; Drug: Rituximab; Drug: Bendamustin Sponsors: Ruijin Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials
Clinical Study of OR for Second-line Treatment of Refractory MZL
Conditions: OR Regimen Refractory Marginal Zone Lymphoma Interventions: Drug: obrutinib, rituximab Sponsors: Lixia Sheng Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 16, 2023 Category: Research Source Type: clinical trials
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Conditions: NHL; Multiple Myeloma; Blood Cancer; Refractory Non-Hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma; Refractory Multiple Myeloma; Relapsed Multiple Myeloma Interventions: Drug: IDP-023; Drug: Rituximab; Drug: Daratumumab; Drug: Interleukin-2; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Mesna Sponsors: Indapta Therapeutics, INC. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
A Study to Learn How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Compared to Rituximab and Chemotherapy in Adult Participants With Previously Untreated Follicular Lymphoma
Conditions: Follicular Lymphoma (FL) Interventions: Drug: Odronextamab; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisone/Prenisolone Sponsors: Regeneron Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 24, 2023 Category: Research Source Type: clinical trials
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Conditions: Diffuse Large B-cell Lymphoma (DLBCL) Interventions: Drug: Odronextamab; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisone/Prednisolone Sponsors: Regeneron Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials
A Trial to Learn if Odronextamab is Safe and Well-tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma
Conditions: Follicular Lymphoma (FL) Interventions: Drug: Odronextamab; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisone/prednisolone; Drug: Bendamustine Sponsors: Regeneron Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Conditions: Relapsed/Refractory Non-Hodgkin Lymphoma Interventions: Drug: BMS-986458; Drug: Rituximab Sponsors: Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials
A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL
Conditions: Diffuse Large B-cell Lymphoma Recurrent; Diffuse Large B Cell Lymphoma Refractory Interventions: Drug: Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin Sponsors: Zhejiang Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 17, 2023 Category: Research Source Type: clinical trials
